What's Happening?
Aurion Biotech, a company specializing in regenerative cell therapy for vision restoration, is set to present at two major ophthalmology meetings in June 2026. The company will participate in the Eye Bank Association of America (EBAA) Annual Meeting in Indianapolis
and the American-European Congress of Ophthalmic Surgery (AECOS) European Symposium in Madrid. Aurion Biotech will discuss its innovative corneal endothelial cell therapy, which aims to address the high unmet needs of patients with corneal endothelial disease. This condition affects millions worldwide and often requires corneal transplants, which are limited by donor availability. Aurion's therapy, AURN001, is designed to regenerate corneal clarity and vision, potentially transforming treatment by reducing the need for donor tissue.
Why It's Important?
Aurion Biotech's advancements in corneal therapy are crucial as they offer a potential solution to the global shortage of donor corneas. With only one donor cornea available for every 70 diseased eyes, the company's regenerative cell therapy could significantly expand access to treatment for patients with corneal endothelial disease. This innovation not only promises to improve patient outcomes but also to alleviate the burden on eye banks and healthcare systems. By presenting at these prestigious meetings, Aurion Biotech is poised to influence the field of ophthalmology and promote the adoption of its therapy, which has already shown promising results in clinical trials and is approved in Japan under the name Vyznova.
